We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Interleukin-2 Suggested as Basis for Celiac Disease Diagnostic Test

By LabMedica International staff writers
Posted on 19 Aug 2019
A study designed to link changes in cytokine release following ingestion of gluten by individuals suffering from celiac disease found that interleukin-2 (IL-2) was the earliest and most prominent cytokine.

Investigators at the biotechnology company ImmusanT (Cambridge, MA, USA), the Walter and Eliza Hall Institute (Melbourne, Australia), and collaborators in the United States and Norway were searching for biomarkers that could be used in a simple blood test for diagnosis of celiac disease.

Currently, diagnosis of celiac disease is typically made by a combination of blood antibody tests and intestinal biopsies, augmented by specific genetic testing. More...
This approach is complicated by the fact that frequently the autoantibodies in the blood are negative, and many individuals have only minor intestinal changes with normal villi. Some celiac sufferers may have severe symptoms and be investigated for years before a diagnosis is achieved. Increasingly, diagnosis of celiac disease is being made in asymptomatic individuals, as a result of screening. Evidence regarding the effects of screening, however, has not been sufficient to determine its usefulness.

For the current study, the investigators injected celiac patients with gluten peptides, which induced gastrointestinal symptoms, particularly nausea and vomiting. In the second phase of the study, the patients consumed a diet including gluten.

Results revealed that peptide injection elevated at least 15 plasma cytokines, with IL-2, IL-8, and IL-10 being most prominent (fold-change increase at four hours of 272, 11, and 1.2, respectively). IL-2 and IL-8 were the only cytokines elevated at two hours, preceding onset of symptoms. After gluten ingestion, IL-2 was the earliest and most prominent cytokine (15-fold change at four hours).

Senior author Dr. Robert P. Anderson, chief scientific officer of ImmusanT, said, "For the first time we have described the inflammatory reaction that patients with celiac disease experience in the immediate hours after they are exposed to gluten. The unpleasant symptoms associated with the disease are linked to an increase in inflammatory molecules in the bloodstream, such as interleukin-2 (IL-2), produced by T-cells of the immune system. This response is similar to what happens when an infection is present, however for people with celiac disease, gluten is the trigger. This information underpins a potential new approach to diagnosis that addresses the emerging medical need to identify patients without celiac disease who may be better served by other treatments for their chronic symptoms."

Contributing author Dr. Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute, said, "For the many people following a gluten-free diet without a formal diagnosis of celiac disease, all that might be required is a blood test before, and four hours after, a small meal of gluten. This would be a dramatic improvement on the current approach, which requires people to actively consume gluten for at least several weeks before undergoing an invasive procedure to sample the small intestine."

The study was published in the August 7, 2019, online edition of the journal Science Advances.

Related Links:
ImmusanT
Walter and Eliza Hall Institute


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.